FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: PeakClear all
CYTALUX
pafolacianine injection
Peak
INTRAVENOUS · SOLUTION
ovarian cancer
2021
NDA
0/100
DAKLINZA
daclatasvir dihydrochloride
Peak
Bristol Myers Squibb
ORAL · TABLET
2015
NDA
0/100
DAPTOMYCIN
daptomycin
Peak
Hikma
INTRAVENOUS · POWDER
pneumonialeft-sided infective endocarditis due to S+13
2023
NDA
0/100
DAPTOMYCIN
daptomycin
Peak
Pfizer
INTRAVENOUS · POWDER
pneumonialeft-sided infective endocarditis due to S+15
2021
NDA
0/100
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE
daptomycin in sodium chloride
Peak
Baxter
INTRAVENOUS · SOLUTION
pneumonialeft-sided infective endocarditis due to S+17
2022
NDA
0/100
DAPZURA RT
daptomycin in sodium chloride
Peak
Baxter
INTRAVENOUS · POWDER
pneumonialeft-sided infective endocarditis due to S+17
2022
NDA
0/100
DAURISMO
glasdegib
Peak
Pfizer
ORAL · TABLET
leukemia
2018
NDA
0/100
DAYBUE
trofinetide
Peak
Acadia Pharmaceuticals
ORAL · SOLUTION
Rett syndrome in adultsolder
2023
PeptideNDA
0/100
DAYVIGO
lemborexant
Peak
Eisai
ORAL · TABLET
characterized by difficulties with sleep onset and/or sleep maintenanceinsomnia
2019
NDA
0/100
DEFINITY
perflutren
Peak
Lantheus Medical Imaging
INTRAVENOUS · INJECTABLE
2001
NDA
0/100
DEFINITY RT
perflutren
Peak
Lantheus Medical Imaging
INTRAVENOUS · INJECTABLE
2001
NDA
0/100
DEFITELIO
defibrotide sodium
Peak
Jazz Pharmaceuticals
INTRAVENOUS · SOLUTION
knownrenal+1
2016
NDA
0/100
DELSTRIGO
doravirine, lamivudine, and tenofovir disoproxil fumarate
Peak
Merck & Co.
ORAL · TABLET
2018
NDA
0/100
DESCOVY
emtricitabine and tenofovir alafenamide
Peak
Gilead Sciences
ORAL · TABLET
HIV-1 infection in pediatric patients weighing at least 14 kg to less than 35 kg in combination with other antiretroviral agentsincluding darunavir+8
2016
NDA
0/100
DETECTNET
copper cu 64 dotatate
Peak
Curium Pharma
INTRAVENOUS · SOLUTION
2020
NDA
0/100
DEXILANT
dexlansoprazole
Peak
Takeda
ORAL · CAPSULE, DELAYED RELEASE
older for: Healing of all grades of erosive esophagitis (EE)older for healing of all grades of erosive esophagitis (EE) for up to eight weeks+4
2009
SMNDA
0/100
DEXMEDETOMIDINE HYDROCHLORIDE
dexmedetomidine
Peak
R-Pharm US
INTRAVENOUS · SOLUTION
2015
NDA
0/100
DEXTENZA
dexamethasone
Peak
Ocular Instruments
OPHTHALMIC · INSERT
ocular inflammationpain following ophthalmic surgery ()+2
2018
NDA
0/100
DEXYCU KIT
dexamethasone
Peak
INTRAOCULAR · SUSPENSION
postoperative inflammationpostoperative inflammation ( )
2018
NDA
0/100
DHIVY
carbidopa levodopa
Peak
ORAL · TABLET
Parkinson's diseasepost-encephalitic parkinsonism+2
2021
NDA
0/100
DIFICID
fidaxomicin
Peak
ORAL · FOR SUSPENSION
older for the treatment of C
2020
NDA
0/100
DILAUDID
hydromorphone hydrochloride
Peak
Fresenius Kabi
INJECTION · INJECTABLE
pain severe enough to require an opioid analgesicfor which alternate treatments are inadequate
1984
NDA
0/100
DILAUDID-HP
hydromorphone hydrochloride
Peak
Fresenius Kabi
INJECTION · INJECTABLE
pain severe enough to require an opioid analgesicfor which alternate treatments are inadequate
1984
NDA
0/100
DOCETAXEL
docetaxel
Peak
Medica Corp
INJECTION · INJECTABLE
metastatic breast cancer after failure of prior chemotherapymetastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy+6
2015
NDA
0/100
← PreviousPage 30 of 55Next →